Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

GSK sells partial stake in spin-off firm Haleon at discount

Published 05/11/2023, 12:27 PM
Updated 05/12/2023, 03:25 AM
© Reuters. GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration

(Reuters) -British drugmaker GSK on Friday said it sold 240 million shares in its consumer healthcare business Haleon at 335 pence per share, raising about 804 million pounds ($1.01 billion).

Haleon, the world's biggest standalone consumer health company, comprising assets from GSK and Pfizer (NYSE:PFE), sells non-prescription drugs, vitamins and oral care products.

The sale price represents a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday and lowers the stake of GSK, the second largest shareholder, to 10.3%.

Haleon shares were up 1.6% at 348 pence in early trade on Friday.

Last week, the firm reported quarterly profit below expectations as higher costs squeezed margins.

Sensodyne maker Haleon was formed in July 2019 as GSK and Pfizer merged their consumer healthcare businesses. It was spun out and listed on the London Stock Exchange in July 2022.

GSK and Pfizer have agreed to not sell any further Haleon shares for 60 days.

© Reuters. GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration

Pfizer told the Financial Times newspaper last week that it intends to offload its stake in a "slow and methodical" manner within months.

($1 = 0.7923 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.